Johnson & Johnson to Acquire Ollin Biosciences

Johnson & Johnson will acquire Texas-based biotechnology company Ollin Biosciences. The company will initially pay $2.2 billion, with an additional payment of approximately $1.13 billion contingent on the results of Ollin's drug research and sales.
Ollin's lead drug, OLN324, is being developed to treat two eye diseases that cause vision loss over time and affect more than 40 million people worldwide.
Early research showed that OLN324 outperformed Roche's Vabysmo on several metrics, though the drug still needs to complete the final stage of clinical trials.
Blackstone Life Sciences will also participate in funding the research, providing Johnson & Johnson with $750 million over several years. If the drug proves successful, Blackstone will also receive a share of future revenue.
The acquisition of Ollin is expected to close by the end of 2026.
Source: Yahoo Finance
Get our latest market analysis and financial insights delivered straight to you. No spam — just the signal.





